Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Prescription stimulant medication misuse: Where are we and where do we go from here?

Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Rathkey ES, McCallum A.

Exp Clin Psychopharmacol. 2016 Oct;24(5):400-414.

PMID:
27690507
2.

Pharmacological Neuroenhancement: teachers' knowledge and attitudes-Results from a survey study among teachers in Germany.

Franke AG, Lehmberg S, Soyka M.

Subst Abuse Treat Prev Policy. 2016 Sep 20;11(1):32. doi: 10.1186/s13011-016-0077-y.

4.

Emerging Therapeutic Enhancement Enabling Health Technologies and Their Discourses: What Is Discussed within the Health Domain?

Wolbring G, Diep L, Yumakulov S, Ball N, Leopatra V, Yergens D.

Healthcare (Basel). 2013 Jul 25;1(1):20-52. doi: 10.3390/healthcare1010020.

5.

EEG and Eye Tracking Demonstrate Vigilance Enhancement with Challenge Integration.

Bodala IP, Li J, Thakor NV, Al-Nashash H.

Front Hum Neurosci. 2016 Jun 7;10:273. doi: 10.3389/fnhum.2016.00273.

6.

Moral and social reasons to acknowledge the use of cognitive enhancers in competitive-selective contexts.

Garasic MD, Lavazza A.

BMC Med Ethics. 2016 Mar 29;17:18. doi: 10.1186/s12910-016-0102-8.

7.
8.
9.

Pharmacology, physiology and performance: occupational drug use and HIV risk among female entertainment and sex workers in Cambodia.

Dixon TC, Ngak S, Stein E, Carrico A, Page K, Maher L.

Harm Reduct J. 2015 Oct 16;12:33. doi: 10.1186/s12954-015-0068-8.

10.

Cognition and the Placebo Effect--Dissociating Subjective Perception and Actual Performance.

Schwarz KA, Büchel C.

PLoS One. 2015 Jul 6;10(7):e0130492. doi: 10.1371/journal.pone.0130492.

11.

Pharmacological Cognitive Enhancement in Healthy Individuals: A Compensation for Cognitive Deficits or a Question of Personality?

Maier LJ, Wunderli MD, Vonmoos M, Römmelt AT, Baumgartner MR, Seifritz E, Schaub MP, Quednow BB.

PLoS One. 2015 Jun 24;10(6):e0129805. doi: 10.1371/journal.pone.0129805.

12.

Neurolaw: A brief introduction.

Petoft A.

Iran J Neurol. 2015 Jan 5;14(1):53-8.

13.
14.

"Messing with the mind": evolutionary challenges to human brain augmentation.

Saniotis A, Henneberg M, Kumaratilake J, Grantham JP.

Front Syst Neurosci. 2014 Sep 30;8:152. doi: 10.3389/fnsys.2014.00152.

15.
16.

To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students.

Maier LJ, Liechti ME, Herzig F, Schaub MP.

PLoS One. 2013 Nov 13;8(11):e77967. doi: 10.1371/journal.pone.0077967.

17.

Enhancement stimulants: perceived motivational and cognitive advantages.

Ilieva IP, Farah MJ.

Front Neurosci. 2013 Oct 31;7:198. doi: 10.3389/fnins.2013.00198.

18.

A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.

del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron JC, Aigbirhio FI, Robbins TW, Sahakian BJ, Müller U.

Brain. 2013 Nov;136(Pt 11):3252-70. doi: 10.1093/brain/awt263.

19.

Roles of adrenergic α1 and dopamine D1 and D2 receptors in the mediation of the desynchronization effects of modafinil in a mouse EEG synchronization model.

Chen CR, Yang SR, Liu YY, Qu WM, Urade Y, Huang ZL.

PLoS One. 2013 Oct 7;8(10):e76102. doi: 10.1371/journal.pone.0076102.

20.

Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement.

Sattler S, Forlini C, Racine E, Sauer C.

PLoS One. 2013 Aug 5;8(8):e71452. doi: 10.1371/journal.pone.0071452.

Items per page

Supplemental Content

Support Center